Episode Details

A Spanish research team achieved remarkable results, making pancreatic cancer tumors disappear in mice by targeting multiple escape routes simultaneously. This approach prevented tumor recurrence and resistance, highlighting a design strategy central to precision cancer medicine.

Dr. Dino Prato discusses how this mirrors the principles of targeted cancer therapy, emphasizing the importance of understanding the tumor microenvironment for effective cancer care.

🎯 What You’ll Learn in This Episode:
- Why pancreatic cancer is so difficult to treat
- What KRAS, EGFR, and STAT3 do
- How tumors develop resistance
- What the triple-lock strategy means
- Why mouse data doesn’t always translate to humans
- The difference between one-size-fits-all and precision oncology
- Why immune activation matters for long-term control
- Questions to ask your doctor about pathway targeting

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Cancer adapts — so treatment must adapt faster.”

Disclaimer

This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied

Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493